Showing results (131-140 of 386) with videos related to

Sort By:
Pageof 39
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cellMarcus O Butler, Jeng-Shin Lee, Sascha Ansén, et al.
Cancer Immunology Research|April 30, 2014
Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumabJianda Yuan, Jun Zhou, Zhiwan Dong, et al.
Cancer Immunology Research|February 12, 2016
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung CancerMizuki Nishino, Emily S Chambers, Curtis R Chong, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibitionJianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
STAR Protocols|March 4, 2022
Mass cytometry staining for human bone marrow clinical samplesMargaret Hallisey, Jenna Dennis, Charlotte Abrecht, et al.
Cancer|September 14, 2020
Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastasesJack M Qian, Allison M Martin, Kate Martin, et al.
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
Cancer Research Communications|April 29, 2024
A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal MelanomaElizabeth I Buchbinder, Justine V Cohen, Giuseppe Tarantino, et al.
Cancer Immunology Research|March 2, 2017
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsGuillermo De Velasco, Youjin Je, Dominick Bossé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2020
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib StudyJohn W Moroney, John Powderly, Christopher H Lieu, et al.
Pageof 39